Search alternatives:
point decrease » point increase (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
401
-
402
-
403
Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
404
Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
405
-
406
-
407
-
408
-
409
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
-
410
-
411
HDM exposure results in increased MIP-2 and decreased IFNα and IL-13.
Published 2014“…HDM exposure increased bronchoalveolar lavage MIP-2 (A), and decreased IFNα (B) and IL13 (C). There was no effect of HDM exposure on BAL protein (D), nor were there any effects of HRV-1B infection alone, or combined effects of HDM exposure and HRV-1B infection on any of these parameters. * indicates a significant difference between groups. …”
-
412
-
413
-
414
-
415
Propofol increased the number of the hippocampal pyramidal neurons and decreased the expression of the LC3-II protein and the number of lysosomes and autophagosomes in the ischemic...
Published 2013“…<p>I/R was induced by 2-vessel occlusion. Propofol 10, 50, or 100 mg/kg was administrated intraperitoneally and 3-MA (600 nM) was administered intracerebroventricularly 10 min after the onset of ischemia. (1) Sham-operated group (control group, Cont); (2) I/R group; (3) I/R+ 3-MA 600 nmol group; (4) I/R + propofol 10 mg/kg group; (5) I/R + propofol 50 mg/kg group; (6) I/R + propofol 100 mg/kg group; (7) I/R + vehicle (intralipid, 100 mg/kg) group. …”
-
416
-
417
-
418
-
419
-
420